UNSPSC 51383303: Amfenac

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28O5C1J38A. European Medicines Agency schedules Amfenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05415MIG. Amfenac generally arises in the molecular formula C15H13NO3.

The term AMFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) AMFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amfenac under HS 29225000 and SITC 51467. As of Q4 2014, AMFENAC remains the US FDA Preferred Term for this commodity. Amfenac bears US NLM identifiers UMLS ID C0051572 and NCI Concept Code C73071. SMILES: O=C(C1C(N)C(CC(=O)O)CCC1)C1CCCCC1.

UNSPSC 51383303 Amfenac is a Commodity code that nominally covers a specific nonsteroidal anti-inflammatory drug, but recent state and local solicitation activity does not reflect purchasing of this pharmaceutical specifically. Instead, the opportunities tagged to this code reveal state and local governments buying naloxone (opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals with various therapeutic indications, and over-the-counter products through cooperative purchasing arrangements and direct health department procurement. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities across multiple states including Oregon). The scope encompasses both emergency-response pharmaceuticals and broader pharmaceutical supply chain agreements with manufacturers, wholesalers, and pharmacy benefit program participants.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, released an RFP (S1070000015802) posted January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026. The code shows limited direct relevance to amfenac specifically; vendors should verify actual product requirements in each solicitation rather than relying on the UNSPSC code classification.